TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05487885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS)
Description: a form of transcranial magnetic stimulation, to dorsomedial prefrontal cortex (dmPFC)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS)
Description: a form of transcranial magnetic stimulation, to dorsomedial prefrontal cortex (dmPFC)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Training
Description: Psychosocial add-on intervention that could enhance the effects of TBS. PA Therapy (Craske et al., 2016) is an innovative cognitive and experiential technique developed to address anhedonia specifically and, ideally, change altered patterns of frontostriatal function. Standing in contrast to Cognitive Behavioral Therapy, PA training has efficacy for enhancing positive affect and reducing negative affect (Craske et al., 2018). This treatment can be easily applied, and we propose that it will enhance neural circuit-level changes elicited by TBS.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Training
Description: Psychosocial add-on intervention that could enhance the effects of TBS. PA Therapy (Craske et al., 2016) is an innovative cognitive and experiential technique developed to address anhedonia specifically and, ideally, change altered patterns of frontostriatal function. Standing in contrast to Cognitive Behavioral Therapy, PA training has efficacy for enhancing positive affect and reducing negative affect (Craske et al., 2018). This treatment can be easily applied, and we propose that it will enhance neural circuit-level changes elicited by TBS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Injectable Solution
Description: Ketamine is FDA-approved as an anesthetic agent that will be used off-label in this study. It is used routinely in both pediatric and adult patients and is considered extremely safe in substantially higher, anesthetic doses. The dose to be administered here (0.5 mg/kg) is a much lower, subanesthetic dose, and the administration route (intravenous) is the standard when used in anesthesia. Published studies and metaanalyses of this dose of intravenous ketamine as an off label use in depression show clearly that there are no increased risks in this population, including a recent study in adolescents (Dwyer et al, 2021, American Journal of Psychiatry). A single dose of ketamine will be used to determine if it alters the functioning of the anhedonia-related reward functioning and frontostriatal biomarkers assessed in this study.
Study: NCT05454046

Intervention type: OTHER
Intervention: Food intake among women and men in fertility treatment
Description: Filling in an FFQ

Intervention type: OTHER
Intervention: Food intake among women and men in fertility treatment
Description: Filling in an FFQ
Study: NCT06328244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple swallowing training
Description: Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week.
Study: NCT06532604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroretinography (ERG)
Description: ERG are specifically carried out for research. They are performed in Nancy with the MonPackOne device developed by Metrovision for participants at center n°1, and in Paris with the RETeval device developed by LKS Technologie for participants at center n°2. Both devices comply with ISCEV standard and are CE marked. They enable the reccord of Pattern ERG, Flash ERG and Multifocal ERG using corneal and skin electrodes, or Sensor Strip skin electrodes only, for the Nancy and Paris centers respectively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroretinography (ERG)
Description: ERG are specifically carried out for research. They are performed in Nancy with the MonPackOne device developed by Metrovision for participants at center n°1, and in Paris with the RETeval device developed by LKS Technologie for participants at center n°2. Both devices comply with ISCEV standard and are CE marked. They enable the reccord of Pattern ERG, Flash ERG and Multifocal ERG using corneal and skin electrodes, or Sensor Strip skin electrodes only, for the Nancy and Paris centers respectively.
Study: NCT05455359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Prucalopride 0.04 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Prucalopride 0.04 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Famotidine 0.4 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Famotidine 0.4 mg/kg/day
Study: NCT06475885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Massage Program
Description: The experimental group received the International Association of Infant Massage (IAIM) Infant Massage Program starting from day 14 postpartum for a duration of 5 weeks.
Study: NCT05836857

Intervention type: BEHAVIORAL
Intervention: Cannabis (Marijuana)
Description: The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education.

Intervention type: BEHAVIORAL
Intervention: Cannabidiol (CBD)
Description: The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education
Study: NCT05428202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GN037
Description: GN-037 cream containing urea, salicylic acid, retinoic acid and clobetasol 17-propionate and matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cream containing base without active ingredients
Study: NCT06366139

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency thermocoagulation of the trigeminal ganglion
Description: The patient is placed in the supine position and the foramen ovale is identified medial to the coronoid process of the mandible by giving the head a submental oblique position under fluoroscopic guidance. A 20-gauge, 5 mm active type, and 100 mm radiofrequency cannula is inserted 2 cm lateral to the commissura labialis and advanced towards the foramen. After entering the foramen ovale with a lateral fluoroscopic image, the radiofrequency cannula is connected to the radiofrequency generator and sensory and motor stimulations are performed to confirm the target maxillary and mandibular nerves. The radiofrequency lesion is applied at 60°C, 65°C and 70°C for 60-seconds periods. The patient is observed for side effects for 1 hour after the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary/Mandibular nerve pulsed radiofrequency
Description: The patient is placed in the lateral decubitus position with the affected side up. A 5-12 MHz linear ultrasound probe is placed in the infrazygomatic area above the maxilla at a 45° inclination in both the frontal and horizontal planes. The probe position allows visualization of the pterygopalatine fossa, which is limited to the maxilla anteriorly and the greater wing of the sphenoid posteriorly. Real-time ultrasound guidance allows direct localization of the internal maxillary artery and identification of the needle tip. The radiofrequency cannula was connected to the radiofrequency generator and PRF was applied at 42°C for 240 seconds after confirming the localization of the maxillary and mandibular nerve by obtaining appropriate responses to sensory and motor stimulation.
Study: NCT06207240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroLife FES Sleeve / NeuroLife EMG-FES Sleeve
Description: Electrical stimulation will be delivered via the NeuroLife FES Sleeve and NeuroLife EMG-FES Sleeve devices to assist with movement during functional task practice.
Study: NCT06302296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: injectable form of PRF
Description: A group of patients in which participants will be undergo to orthodontic treatment will be received a 0.9 ml injection of PRF after 1st premolar extraction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo injection
Description: A group of patients in which participants will be undergo to traditional orthodontic treatment will be received a Placebo injection after 1st premolar extraction.
Study: NCT06011304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Florastamin Injection
Description: The subjects who participate in phase 3 study will be intravenously injected with \[18F\]Florastamin Injection and undergo PET/CT scan at 110 min after the injection.~Subjects who participate in pilot study will be intravenously injected with \[18F\]Florastamin Injection and undergo PET/CT scan at 5 min, 30 min, 60 min, 110 min, 160 min after the injection.
Study: NCT05520970

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCLD-CoV19-1
Description: All 200 participants will receive 2 doses of investigational product by 2 months interval via intramuscular injection in the deltoid region

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCLD-CoV19-1
Description: All 200 participants will receive 2 doses of investigational product by 2 months interval via intramuscular injection in the deltoid region

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AdCLD-CoV19-1
Description: All 200 participants will receive 2 doses of investigational product by 2 months interval via intramuscular injection in the deltoid region
Study: NCT06526650

Intervention type: OTHER
Group type: OTHER
Intervention: 'Ai Pono
Description: Hands-on Cooking and Cultural Lessons These lessons will be widely advertised. Each 2-hour presentation will involve hands-on cooking demonstrations and tastings, accompanied by lessons on the cultural significance of featured food items. Demonstrations will link the consumption of vegetables (e.g., sweet potato, breadfruit, kalo) to Native Hawaiian (NH) history and traditional beliefs to help participants rediscover their heritage through the meals they prepare.
Study: NCT04885894

Intervention type: DRUG
Intervention: Zeposia
Description: Participants with MS will be divided into two treatment groups: those who will begin to take Zeposia, and those who plan to be begin treatment with high dose oral efficacy medication. The HC group will be free of neurological disease or injury and will be matched to the MS groups for age, gender, and education.
Study: NCT04416737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultra-rapid insulin
Description: Following 0.5-3 hours of insulin suspension from insulin pump, participants will receive insulin injection in respective locations (separated by at least 1 week) and then have serial lab measurements (YSI glucose, insulin and glucagon) taken during induced hypoglycemia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultra-rapid insulin
Description: Following 0.5-3 hours of insulin suspension from insulin pump, participants will receive insulin injection in respective locations (separated by at least 1 week) and then have serial lab measurements (YSI glucose, insulin and glucagon) taken during induced hypoglycemia.
Study: NCT06617351

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Gummy - 7.5 kilocalories (kCal), 2 g Carbohydrate, 1.5 g total sugars, 7.5 mg sodium, 5 mg melatonin.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gummy - 12.5 kilocalories (kCal), 3g Carbohydrate, 1.875 g total sugars, 1.25 mg sodium.
Study: NCT06612463

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine 6mg/kg
Description: In the caffeine trial, participants ingested a capsule containing 3 mg/kg caffeine 60 min prior to each rugby sevens match. There was 2 matches per day. So the total dosage is 6 mg/kg/ day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo trial, participants ingested a capsule containing starch 60 min before each rugby sevens match. There were 2 matches per day
Study: NCT06620315

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: RBM
Description: Resorbable Blast Media (RBM) implant surfaces can enhance osseointegration and implant stability

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: sand blasted implant
Description: sand blasted implant
Study: NCT06620913

Intervention type: OTHER
Intervention: Description of clinical, immunological and tumor features of patients harboring CV2 Abs
Description: This is a non-interventional study involving clinical data and biological samples (DNA and tumors block). Demographic and clinical data already collected in the database of the French Reference Center on PNS will be reviewed. The diagnostic tests performed to detect CV2-Abs in the patients already included in the database of the French Reference Center on PNS will be retrospectively analyzed.
Study: NCT06618378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback exercise combined with breathing exercise
Description: Urotherapy training will be given at the beginning of the treatment process. Contraction and relaxation will be applied around the external sphincter in combination with diaphragmatic breathing by visual imagery with EMG biofeedback application. The second channel EMG will be placed on the transversus abdominus muscle and its activation will be checked. The treatment will be completed with 30-minute sessions twice a week for 12 weeks. Each session will consist of 40 cycles of 10 minutes of diaphragmatic breathing exercise followed by 20 minutes of 10 seconds of contraction followed by 20 seconds of relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: urotherapy educational group
Description: 1. An important part of urotherapy is to provide parents and children with detailed explanations of etiology, prevalence and pathophysiology. This will reassure parents and help them understand the causes of the child's bedwetting accidents and the rationale for treatment. This will increase compliance with treatment.~2. Recommendations are given regarding appropriate fluid intake and regular voiding throughout the day. The child is encouraged to go to the toilet seven times a day and drink seven glasses of water.~3. The correct sitting position for the toilet is explained. If the feet do not touch the floor easily, it is recommended to use a step stool for foot support. Additionally, children are taught to relax their abdomen when peeing.~4. In addition to monitoring and motivation, a bladder diary should be kept to give the child and parents an idea about the progress of treatment, compliance with treatment and continuity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: urotherapy educational group
Description: 1. An important part of urotherapy is to provide parents and children with detailed explanations of etiology, prevalence and pathophysiology. This will reassure parents and help them understand the causes of the child's bedwetting accidents and the rationale for treatment. This will increase compliance with treatment.~2. Recommendations are given regarding appropriate fluid intake and regular voiding throughout the day. The child is encouraged to go to the toilet seven times a day and drink seven glasses of water.~3. The correct sitting position for the toilet is explained. If the feet do not touch the floor easily, it is recommended to use a step stool for foot support. Additionally, children are taught to relax their abdomen when peeing.~4. In addition to monitoring and motivation, a bladder diary should be kept to give the child and parents an idea about the progress of treatment, compliance with treatment and continuity.
Study: NCT06618430

Intervention type: OTHER
Intervention: None (Observational Study)
Description: None (Observational Study)

Intervention type: OTHER
Intervention: None (Observational Study)
Description: None (Observational Study)

Intervention type: OTHER
Intervention: None (Observational Study)
Description: None (Observational Study)

Intervention type: OTHER
Intervention: None (Observational Study)
Description: None (Observational Study)
Study: NCT06624150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS sessions, StarStim device
Description: 10 active sessions of transcranial direct current stimulation paired with cognitive training tasks. Device used is StarStim.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (fake) tDCS sessions
Description: 10 fake sessions of transcranial direct current stimulation paired with cognitive training tasks. The device will be on the participants head, but the current will not be active.
Study: NCT06622473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hand dexterity assessement
Description: Each participant will perform the VET, with their most affected hand, followed by the VET with the less affected hand.
Study: NCT06241261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride gel
Description: Application of 38% SDF gel every 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver diamine fluoride solution
Description: Application of 38% SDF solution every 6 months
Study: NCT06624189

Intervention type: OTHER
Intervention: Auto-pended bot liver ultrasound order
Description: This alert prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis.
Study: NCT06622265

Intervention type: DEVICE
Intervention: Electrocardiogram recording
Description: ECG recording with investigational device

Intervention type: DEVICE
Intervention: Electrocardiogram recording
Description: ECG recording with investigational device
Study: NCT06624241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipo-Curcumin gel + SRP
Description: The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of Lipo- Curcumin gel. The pocket will be sealed with cyanoacrylate.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lipo gel + SRP
Description: The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of Lipo gel. The pocket will be sealed with cyanoacrylate.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discharged Gel + SRP
Description: The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of discharged gel. The pocket will be sealed with cyanoacrylate.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP alone
Description: The pocket defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and no further treatment will be performed.
Study: NCT06623565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multimodal image-guided resection
Description: Supramarginal resection using combination of ADC MRI and FET PET
Study: NCT06624293

Intervention type: DIAGNOSTIC_TEST
Intervention: BNP
Description: Blood collected during this study will be tested on separate IUO BNP assay on a separate protocol. No active interventions will occur during this study.
Study: NCT06628778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: Dalteparin thromboprophylaxis administered subcutaneously twice daily (every 12 hours) from enrollment through pediatric intensive care unit discharge
Study: NCT04682652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embozene MicroSpheres
Description: Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery in the knee going to the region of pain. One of the causes of pain in the setting of knee arthritis is increased blood flow going to the specific area of pain. The goal of this procedure is to decrease the blood flow (embolize) to the specific region of the knee that is causing your pain. This is done by infusing Embozene particles into the specific blood vessel (genicular artery) supplying the area of pain in the knee.
Study: NCT06263270

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CYT-108, a recombinant protease inhibitor
Description: CYT-108 is a recombinant alpha-2-macroglobulin (A2M) variant engineered with increased potency against A Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS) substrates while possessing strong activity against Matrix Metalloproteinases (MMPs) and serine proteases. This A2M variant was engineered with amino acid modifications to the bait region (i.e., protease-binding region) of the A2M protein to make the variant at least two fold more effective in inhibiting ADAMTSs compared to wt-A2M without affecting its inhibitory activity toward other proteases (see Investigator Brochure). CYT-108 is not expected to cure osteoarthritis (OA), but it is expected to be the first treatment to slow disease progression by inhibiting cartilage breakdown, resulting in clinically significant outcomes such as pain reduction and improvement in mobility. This hypothesis is supported by our preliminary findings in multiple safety and efficacy studies conducted in rat and canine models of OA.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffered Saline (PBS)
Description: Phosphate Buffered Saline (PBS)
Study: NCT05415371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care + Financial Incentives
Description: Financial incentive participants will receive standard care and receive incentives for completing counseling calls and for abstinence.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.